...
首页> 外文期刊>International Journal of Cardiology >Novel glucose lowering agents are associated with a lower risk of cardiovascular and adverse events in type 2 diabetes: A population based analysis
【24h】

Novel glucose lowering agents are associated with a lower risk of cardiovascular and adverse events in type 2 diabetes: A population based analysis

机译:新型葡萄糖降低剂与2型糖尿病的心血管和不良事件的风险较低有关:基于群体的分析

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Recent randomized control trials have described a protective cardiovascular effect of novel glucose lowering drugs in patients at high cardiovascular risk. Whether these second-line agents have similar effects in the general population is unknown. We aimed to compare the risk of major cardiovascular and adverse events in new users of sodium-glucose cotransporter-2 inhibitors (SGLT-2i), dipeptidyl peptidase-4 inhibitor (DPP-4i), glucagon-like peptide 1 agonist (GLP-1a), and sulfonylurea in T2DM patients not controlled on metformin therapy.
机译:背景:最近的随机对照试验描述了在高心血管风险下患者的新型葡萄糖降低药物的保护性心血管作用。 这些二线剂是否在一般人群中具有类似的效果是未知的。 我们的旨在比较葡萄糖Cotoranger-2抑制剂(SGLT-2I),二肽基肽酶-4抑制剂(DPP-4I),胰高血糖素样肽1激动剂(GLP-1A)的主要心血管和不良事件的风险 ),T2DM患者中的磺脲类脲在二甲双胍疗法上没有控制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号